Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 5/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.46 |
| ▸ | CLK1 | P49759 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PDE5A | O76074 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL590323 | 1.00 | GRM2 (0.47) | GRM2SIGMAR1CLK1LMNAPDE5A | |
| SCHEMBL591827 | 1.00 | GRM2 (0.47) | GRM2SIGMAR1CLK1LMNAPDE5A | |
| SCHEMBL589858 | 0.86 | PDE5A (0.49) | GRM2SIGMAR1CLK1LMNAPDE5A | |
| SCHEMBL590285 | 0.86 | PDE5A (0.49) | GRM2SIGMAR1CLK1LMNAPDE5A | |
| SCHEMBL589860 | 0.86 | PDE5A (0.49) | GRM2SIGMAR1CLK1LMNAPDE5A | |
| SCHEMBL632760 | 0.86 | SIGMAR1 (0.51) | GRM2SIGMAR1CLK1KCNH2 | |
| SCHEMBL632762 | 0.86 | SIGMAR1 (0.51) | GRM2SIGMAR1CLK1KCNH2 | |
| SCHEMBL590021 | 0.85 | GRM2 (0.48) | GRM2SIGMAR1CLK1LMNAKCNH2 | |
| SCHEMBL591586 | 0.85 | GRM2 (0.48) | GRM2SIGMAR1CLK1LMNAKCNH2 | |
| SCHEMBL590023 | 0.85 | GRM2 (0.48) | GRM2SIGMAR1CLK1LMNAKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114867-B2 | Oxazolidinone antibiotic derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2012-02-14 | — | — | US | disclosed |
| US-20100137290-A1 | OXAZOLIDINONE ANTIBIOTIC DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137290-A1 | OXAZOLIDINONE ANTIBIOTIC DERIVATIVES | OXA1L, XDH, CCNY | GRM2 4516/4885SIGMAR1 33/4885CLK1 1494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.